Apr 25, 2024 8:00am EDT Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
Mar 15, 2024 4:30pm EDT Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Dec 21, 2023 7:30am EST Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients
Sep 12, 2023 7:30am EDT Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
Sep 01, 2023 7:30am EDT Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
Aug 03, 2023 7:30am EDT Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid
Jul 18, 2023 7:30am EDT Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities
